Molnupiravir Prescriptive Guidelines Revised Amidst Omicron Surge
- Omicron tally reaches 4,868
- Weekly positivity rate stood at 10% in 120 districts.
- Anti-oral pill Molnupiravir, contraindicated for young patients.
New Delhi: India recorded 1,94,720 fresh infections in the past 24 hours. The recovery rate at 96.01 per cent accounted for 60,405 recuperations in the last 24 hours taking the total recoveries to 3,46,30,536. The daily positivity rate stood at 11.05 per cent.
The number of active cases stood at 9,55,319 accounting for 2.65 per cent of the total number of cases. The active cases reported a rise of 1,33,873 in the last 24 hours. However, the mortality rate recorded at 1.34 per cent reported a spike in deaths recording 442 fatalities, taking the cumulative death toll to 4,84,655. Omicron variant cases tally rose to 4,868 the Union Health Ministry said today morning.
According to a report from the Union Health Ministry, 120 districts in 29 states and UTs have recorded a weekly positivity rate of 10 per cent in the third wave of the pandemic.
Administration of Anti-oral pill Molnupiravir, has been re-categorized by Dr NK Arora, Chairman of COVID-19 Working Group of NTAGI. At a press briefing Dr Arora stated that the oral pill should be prescribed only for geriatric patients with co-morbidities, it should not be given to people of the reproductive age he pressed. Citing the irrational use ‘dangerous’, he said, “Molnupiravir benefits when given at an early stage of the infection. It reduces the possibility of hospitalisation and ICU admissions. Irrational use is dangerous. It will contribute in the treatment of senior citizens, particularly those with comorbidities and if given at an early stage, it will reduce the chances of severe disease. “
The health bulletin documented 153.80 crore cumulative vaccinations under the nationwide vaccination drive, including 85.26 lakh administrations in the past 24 hours.